VRNA Share Price Performance
US$106.91
73.05 (215.74%)
0.6% overvalued intrinsic discount
US$106.22
Fair Value
Price US$106.91
AnalystConsensusTarget US$106.22
Fair ValueUS$106.22
Share PriceUS$106.91
0.6% overvalued intrinsic discount
Verona Pharma plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 23 Fair Values set on narratives written by author
VRNA Community Narratives
AN
Fair Value US$106.22 0.6% overvalued intrinsic discount
Ohtuvayre Launch And EU Approval Will Unlock Future Markets
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Ohtuvayre Launch And EU Approval Will Unlock Future Markets
Key Takeaways Rapid adoption of Ohtuvayre for COPD and strong prescription growth suggest significant future revenue potential. Global regulatory advancements and strategic financing bolster potential for new revenue streams and acquisitions.
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$106.22
0.6% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
83.32% p.a.
Profit Margin
44.9%
Future PE
21.32x
Share price in 2028
US$129.78
Snowflake Analysis
Verona Pharma plc Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.94
- 95.15%
- -36.62%
- 87.1%
About VRNA
- Founded
- 2005
- Employees
- 209
- CEO
- WebsiteView website
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
